Subcutaneous human hepatitis B immunoglobulin: scant assessment after liver transplantation for hepatitis B.
The only (non-comparative) trial of subcutaneous treatment, following intravenous administration, is insufficient to determine the impact on survival, re-infection, or the risk of potentially severe hypersensitivity reactions.